Anupam Rasayan India Ltd. delivered its highest-ever annual performance in FY26, reporting a consolidated revenue of ₹23,836 Mn, a 65% Y-o-Y growth. The company achieved a consolidated EBITDA of ₹5,430 Mn and a Profit After Tax of ₹2,222 Mn, marking a 39% increase. These results were driven by successful new product commercialization, strategic acquisitions like Jayhawk Fine Chemicals, and strong traction across key specialty chemical business verticals.
Annual Financial Performance
For the financial year ended March 31, 2026, Anupam Rasayan reported robust consolidated results. Annual revenue surged to ₹23,836 Mn, representing a strong 65% year-on-year growth. Operating profitability remained healthy with an EBITDA of ₹5,430 Mn (up 32% Y-o-Y). The company also reported a net profit of ₹2,222 Mn, reflecting a 39% Y-o-Y growth. Standalone results were equally impressive, with annual revenues reaching ₹16,955 Mn and a significant 122% growth in Profit After Tax to ₹1,614 Mn.
Strategic Milestones and Acquisitions
The year was defined by critical strategic expansions. The successful acquisition of Jayhawk Fine Chemicals in the U.S. marked a milestone in building a globally integrated specialty chemicals and CDMO platform. Jayhawk contributed strongly with proforma annual revenue of US$ 76 Mn. Additionally, the company signed a definitive agreement to acquire a controlling stake in Bliss GVS Pharma, aimed at expanding capabilities within the pharmaceutical value chain and creating operational synergies.
Operational Excellence and Growth Drivers
Anupam Rasayan continued to scale its operations, delivering its highest-ever operating cash flow of ₹3,343 Mn. The company successfully launched 3 new products during the year, bolstering its high-value specialty chemical portfolio. With over 90+ molecules currently under development and a robust R&D team of over 90 professionals, the company remains well-positioned to leverage its 8 manufacturing plants and advanced fluorination chemistry capabilities to meet future demand in the agrochemical, pharmaceutical, and performance material segments.
Future Outlook
The company maintains a strong order book of ₹14,646 Crores, with multiple projects slated for commercialization in FY27 and FY28. By integrating its supply chain through the Tanfac and Jayhawk acquisitions, Anupam Rasayan is focused on becoming the partner of choice for multinational corporations, supported by a clear path to achieving energy net zero by 2028.
Source: BSE
